The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Centre will enhance Australian clinical immunisation research and training, focussing upon clinical questions with translatable outcomes not easily addressed by industry. Optimal immunisation and interventions to maximise uptake of existing and new vaccines in high risk patient groups, such as children with cancer, immigrants, children with chronic diseases and adolescents will be studied. New vaccine trials, innovative use of existing vaccines, systematic collection of vaccine failure data, ....The Centre will enhance Australian clinical immunisation research and training, focussing upon clinical questions with translatable outcomes not easily addressed by industry. Optimal immunisation and interventions to maximise uptake of existing and new vaccines in high risk patient groups, such as children with cancer, immigrants, children with chronic diseases and adolescents will be studied. New vaccine trials, innovative use of existing vaccines, systematic collection of vaccine failure data, and targeted epidemiology and disease modelling vaccine preventable disease will also allow a broad program of research, enabling training and mentoring of young clinical nurse and physician researchers. Collaborations with existing national immunisation, infectious diseases and research institutions will allow maximal effectiveness of clinical studies.Read moreRead less
Reducing Vaccine Preventable Diseases In Children: Using National Active Hospital-based Surveillance To Evaluate And Improve Immunisation Program Performance
Funder
National Health and Medical Research Council
Funding Amount
$1,049,916.00
Summary
This proposal aims to evaluate and improve upon immunisation policy and programs for the prevention of severe childhood influenza and pertussis. Using our successful Paediatric Active Enhanced Disease Surveillance (PAEDS) network in 6 major children's hospitals across Australia, we will identify gaps in the evidence base needed to better control influenza and pertussis and in particular to ensure programs are delivered in such a way so as to address health inequalities.
Characterization Of Cellular Inflammatory Responses Underlying Acute Viral Bronchiolitis In Infants
Funder
National Health and Medical Research Council
Funding Amount
$583,224.00
Summary
This project seeks to characterize the inflammatory mechanisms triggered during severe respiratory virus infections that result in hospitalization of infants. These are associated with later development of asthma. We aim to identify new molecular targets for anti-inflammatory drug development, with the long term goals of improving treatment for acute disease, and prevention of subsequent asthma.
Evaluation Of The Incorporation Of WHO Guidelines Into Post-graduate Medical Curriculum; The Impact On Quality Of Care
Funder
National Health and Medical Research Council
Funding Amount
$130,704.00
Summary
There is abundant evidence that many patients do not receive medical treatments of proven effectiveness. This is even more apparent in developing countries. Strategies to improve use of proven treatments is needed. Our research aims to evaluate an educational program for doctors in Lao PDR, based on World Health Organisation guidelines for the care of sick children in hospitals, including the impact on the knowledge of doctors and on the quality of care in the hospitals in which they work.
A Multi-centre, Double-blind, Randomised Controlled Trial To Evaluate The Efficacy Of 10 Valent-pneumococcal-Protein D Conjugate Vaccine In Reducing Respiratory Exacerbations In Children Aged ? 18 Months With Suppurative Lung Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,160,660.00
Summary
Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable dir ....Chronic suppurative (ie infected) lung diseases in children are major causes of poor health and deaths worldwide. Repeated childhood infections contribute to poor lung health in adults. The most common organism causing infection is non-typeable Haemophilus influenzae (NTHi). This study aims to determine whether a vaccine against NTHi can reduce repeated respiratory infections in children. If so, vaccination may lead to substantial improvements in current/ future lung health, and considerable direct and indirect cost of disease savings.Read moreRead less
Towards Improved Respiratory Outcomes In Preterm Infants Through Rapid And Effective Aerosalisation Of Medication To The Lung
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Babies born premature are greatest at risk from increasingly common respiratory illnesses. It is possible that delivering a medication by aerosol will be the most effective method of treatment. For premature babies that need breathing support, inhaled medication could improve care. For highly infectious respiratory illnesses such as RSV, with no vaccines available, we need to protect babies very early in life. I will use an established lamb model to test fast medication delivery to the lungs.
The Role Of Emerging Gastrointestinal Viruses In The First Two Years Of Life: A Birth Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$392,534.00
Summary
Gastro illnesses are common and potentially serious early in life. We are aiming to find out more about these illnesses by following ~140 children from birth to their second birthday, with parents collecting a dirty nappy swab every week. Our laboratory will test these samples for a wide range of known and new gastro viruses, and we will also be looking for, as yet, undiscovered viruses. This information will allow us to document the burden of these illnesses in young children and their families ....Gastro illnesses are common and potentially serious early in life. We are aiming to find out more about these illnesses by following ~140 children from birth to their second birthday, with parents collecting a dirty nappy swab every week. Our laboratory will test these samples for a wide range of known and new gastro viruses, and we will also be looking for, as yet, undiscovered viruses. This information will allow us to document the burden of these illnesses in young children and their families.Read moreRead less
A Novel Paradigm For Immunity And Vaccine Development Against Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$491,229.00
Summary
Serious disease caused by the group A streptococcus (GAS) is responsible for more than 500,000 deaths per year. With no effective control strategies available, a vaccine is urgently needed. One vaccine shows great promise, but there are concerns it may not cover all GAS strains. Our project aims to show that the vaccine may in fact have very broad coverage because of cross-protection between strains using natural immunity model, and may lead to a new paradigm in understanding of GAS immunity.